The Third Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer, Shijiazhuang, China.
Eur J Clin Invest. 2024 Aug;54(8):e14201. doi: 10.1111/eci.14201. Epub 2024 Mar 27.
Robotic gastrectomy is increasingly utilized for gastric cancer, but high morbidity remains a concern. Myosteatosis or low skeletal muscle density reflecting fatty infiltration, associates with complications after other cancer surgeries but has not been evaluated for robotic gastrectomy.
This retrospective study analysed 381 patients undergoing robotic gastrectomy for gastric cancer from September 2019 to October 2022. Myosteatosis was quantified on preoperative computed tomography (CT) images at lumbar 3 (L3). Propensity score matching addressed potential confounding between myosteatosis and non-myosteatosis groups. Outcomes were postoperative complications, 30 days mortality, 30 days readmissions and survival.
Myosteatosis was present in 33.6% of patients. Myosteatosis associated with increased overall (47.7% vs. 26.5%, p < 0.001) and severe complications (12.4% vs. 4.9%, p < 0.001). After matching, myosteatosis remained associated with increased overall complications, major complications, intensive care unit (ICU) transfer and readmission (all p < 0.05). Myosteatosis independently predicted overall [odds ratio (OR) = 2.86, 95% confidence interval (CI): 1.57-5.20, p = 0.001] and severe complications (OR = 4.81, 95% CI: 1.51-15.27, p = 0.008). Myosteatosis also associated with reduced overall (85.0% vs. 93.2%, p = 0.015) and disease-free survival (80.3% vs. 88.4%, p=0.029). On multivariate analysis, myosteatosis independently predicted poorer survival [hazard ratio (HR) = 2.83, 95% CI: 1.32-6.08, p=0.012] and disease-free survival (HR = 1.83, 95% CI: 1.01-3.30, p=0.032).
Preoperative CT-defined myosteatosis independently predicts increased postoperative complications and reduced long-term survival after robotic gastrectomy for gastric cancer. Assessing myosteatosis on staging CT could optimize preoperative risk stratification.
机器人胃切除术越来越多地用于治疗胃癌,但高发病率仍然令人担忧。肌肉减少症或低骨骼肌密度反映脂肪浸润,与其他癌症手术后的并发症有关,但尚未对机器人胃切除术进行评估。
本回顾性研究分析了 2019 年 9 月至 2022 年 10 月期间接受机器人胃切除术治疗胃癌的 381 例患者。在术前腰椎 3 节段(L3)的计算机断层扫描(CT)图像上量化肌肉减少症。倾向评分匹配解决了肌肉减少症组和非肌肉减少症组之间的潜在混杂因素。术后并发症、30 天死亡率、30 天再入院率和生存率是主要结局。
33.6%的患者存在肌肉减少症。肌肉减少症与总并发症(47.7%比 26.5%,p<0.001)和严重并发症(12.4%比 4.9%,p<0.001)的发生率增加有关。在匹配后,肌肉减少症仍然与总并发症、主要并发症、重症监护病房(ICU)转移和再入院率增加有关(均 p<0.05)。肌肉减少症独立预测总并发症(优势比[OR]为 2.86,95%置信区间[CI]为 1.57-5.20,p=0.001)和严重并发症(OR 为 4.81,95%CI 为 1.51-15.27,p=0.008)。肌肉减少症还与总生存率(85.0%比 93.2%,p=0.015)和无病生存率(80.3%比 88.4%,p=0.029)降低有关。多变量分析显示,肌肉减少症独立预测生存率降低(风险比[HR]为 2.83,95%CI 为 1.32-6.08,p=0.012)和无病生存率降低(HR 为 1.83,95%CI 为 1.01-3.30,p=0.032)。
术前 CT 定义的肌肉减少症独立预测机器人胃切除术后胃癌术后并发症增加和长期生存率降低。在分期 CT 上评估肌肉减少症可以优化术前风险分层。